Change is coming - whether you like it or not. That’s the gist of HHS Secretary Alex Azar’s statement to a group of hospital executives. Azar is pushing for changes to pricing transparency and other factors affecting the cost of healthcare. Meanwhile, United Healthcare, responding to consumer outcry, will give back much of the cost ...

This week, Innovation Partners’ BioBlog takes a look at the hidden profits in the prescription drug supply chain and Roche’s acquisition of Flatiron, a data firm backed by Google that has made serious inroads into oncology care. An alliance formed by several groups will effectively cover 7 million employees’ healthcare insurance, and more are all ...

This week’s Innovation Partners BioBlog features updates on the White House’s new budget and proposed changes to reimbursement. Anthem backtracks on a controversial decision aimed at reducing emergency room visit. New drugs reach the market, including drugs to treat prostate cancer and more. President’s Budget Proposes Changes to Physician Reimbursement The White House released the ...

What actually causes the high cost of oncology care and other healthcare needs? Is it the changing, uncertain realm of federal regulation or other market forces? An article in this week’s BioBlog from Forbes examines economic forces that may be at work in the market changing the costs of healthcare. ASCO released its clinical pathways ...

In this week’s Innovation Partners BioBlog, we bring you the latest from the world of healthcare. A new head of Health and Human Services was sworn in this week with the Trump Administration promising once again to reduce drug prices. Three global companies joined forces to build their own health insurance plan for over one ...

This week’s Innovation Partners BioBlog is focused on the pharmaceutical industry. Attention now turns to the development of new antibiotics to address antimicrobial resistance, as well as to new and improved treatments for various types of cancer. This and more in the BioBlog. Pharmaceutical Companies Must Do More To Combat Antimicrobial Resistance, Develop New Antibiotics, ...

This week’s Innovation Partners BioBlog focuses on advances in cancer detection and screening. A new blood test identifies eight cancer types that account for 60% or more deaths from cancer each year, while a non-invasive blood test may hold promise for colorectal cancer screening. This and more in this week’s BioBlog. Liquid Biopsy Test Shows ...

In this week’s Innovation Partners BioBlog, we share updates from companies such as Humana, Merck, and Teva. Humana has chosen to exit industry trade group AHIP, while Teva and Merck announce updates on important new drugs. This and more in this week’s Innovation Partners BioBlog. Congressional Advisory Group Supports Changes In Medicare Doctor Payments The ...

This week’s Innovation Partners BioBlog spotlights cancer risks, treatment, and drugs in the news. A new study out of China that assessed nearly 4 million women working long-term night shifts found an increased risk of cancer. New medications are on the horizon, while the J.P. Morgan Healthcare Conference begins in San Francisco. This week’s headlines ...

Cancer deaths have dropped to their lowest rate since 1991, mostly in part to fewer Americans smoking. This week’s BioBlog is filled with more good news from the world of oncology and cancer treatment, including advances in the treatment of breast cancer, renal cell carcinoma, squamous cell carcinoma, and brain tumors. FDA Clears Stereotactic Radiotherapy ...